WO2010066684A3 - Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease - Google Patents

Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease Download PDF

Info

Publication number
WO2010066684A3
WO2010066684A3 PCT/EP2009/066540 EP2009066540W WO2010066684A3 WO 2010066684 A3 WO2010066684 A3 WO 2010066684A3 EP 2009066540 W EP2009066540 W EP 2009066540W WO 2010066684 A3 WO2010066684 A3 WO 2010066684A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pyridyloxyindoles
vegf
inhibitors
disease
Prior art date
Application number
PCT/EP2009/066540
Other languages
French (fr)
Other versions
WO2010066684A2 (en
Inventor
Gerald David Artman Iii
Jason Matthew Elliott
Nan JI
Donglei Liu
Fupeng Ma
Nello Mainolfi
Erik Meredith
Karl Miranda
James J. Powers
Chang Rao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42034535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010066684(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201107299A priority Critical patent/UA107451C2/en
Priority to SG2011036878A priority patent/SG171784A1/en
Priority to CU2011000129A priority patent/CU24097B1/en
Priority to EP09774876.8A priority patent/EP2376478B1/en
Priority to MX2011006093A priority patent/MX2011006093A/en
Priority to BRPI0922552A priority patent/BRPI0922552A2/en
Priority to JP2011540046A priority patent/JP5580330B2/en
Priority to RS20170576A priority patent/RS56076B1/en
Priority to CA2745922A priority patent/CA2745922C/en
Priority to NZ593030A priority patent/NZ593030A/en
Priority to SI200931684A priority patent/SI2376478T1/en
Priority to AU2009326110A priority patent/AU2009326110B9/en
Priority to ES09774876.8T priority patent/ES2633959T3/en
Priority to LTEP09774876.8T priority patent/LT2376478T/en
Priority to PL09774876T priority patent/PL2376478T3/en
Priority to CN200980156323.7A priority patent/CN102307870B/en
Priority to KR1020117015822A priority patent/KR101345956B1/en
Priority to EA201100873A priority patent/EA019681B1/en
Priority to DK09774876.8T priority patent/DK2376478T3/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2010066684A2 publication Critical patent/WO2010066684A2/en
Publication of WO2010066684A3 publication Critical patent/WO2010066684A3/en
Priority to ZA2011/03759A priority patent/ZA201103759B/en
Priority to TN2011000263A priority patent/TN2011000263A1/en
Priority to IL213068A priority patent/IL213068A/en
Priority to HRP20171075TT priority patent/HRP20171075T1/en
Priority to CY20171100772T priority patent/CY1119091T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

The invention relates to novel organic compounds of formula (I), and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
PCT/EP2009/066540 2008-12-09 2009-12-07 Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease WO2010066684A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
UAA201107299A UA107451C2 (en) 2008-12-09 2009-07-12 Pyridyloxyindoles - inhibitors of vegf-r2 and their use for the treatment of disease
LTEP09774876.8T LT2376478T (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
PL09774876T PL2376478T3 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CU2011000129A CU24097B1 (en) 2008-12-09 2009-12-07 PIRIDILOXI-INDOLES COMPOUNDS REPLACED AS VEGF-R2 INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN200980156323.7A CN102307870B (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease
BRPI0922552A BRPI0922552A2 (en) 2008-12-09 2009-12-07 Vegf-r2 pyridyloxyindole inhibitors and their use, pharmaceutical composition and combination, and kit
JP2011540046A JP5580330B2 (en) 2008-12-09 2009-12-07 Pyridyloxindole inhibitors of VEGF-R2 and their use for the treatment of disease
RS20170576A RS56076B1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CA2745922A CA2745922C (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
NZ593030A NZ593030A (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
SI200931684A SI2376478T1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
AU2009326110A AU2009326110B9 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease
ES09774876.8T ES2633959T3 (en) 2008-12-09 2009-12-07 VEGF-R2 pyridyloxy-indole inhibitors and use thereof for the treatment of diseases
SG2011036878A SG171784A1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP09774876.8A EP2376478B1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2011006093A MX2011006093A (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease.
KR1020117015822A KR101345956B1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201100873A EA019681B1 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles - inhibitors of vegf-r2 and use thereof for treatment of disease
DK09774876.8T DK2376478T3 (en) 2008-12-09 2009-12-07 Pyridyloxyindoline inhibitors for VEGF-R2 and its use in the treatment of diseases
IL213068A IL213068A (en) 2008-12-09 2011-05-23 Pyridyloxyindole inhibitors of vegf-r2 and use thereof for treatment of disease
ZA2011/03759A ZA201103759B (en) 2008-12-09 2011-05-23 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
TN2011000263A TN2011000263A1 (en) 2008-12-09 2011-05-23 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
HRP20171075TT HRP20171075T1 (en) 2008-12-09 2017-07-12 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CY20171100772T CY1119091T1 (en) 2008-12-09 2017-07-19 PYRIDYLOXYCHOLOGES AS SUSPENSIONS TOY VEGF-R2 AND USE IN PATIENT TREATMENT

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20124308P 2008-12-09 2008-12-09
US61/201,243 2008-12-09
US23334109P 2009-08-12 2009-08-12
US61/233,341 2009-08-12

Publications (2)

Publication Number Publication Date
WO2010066684A2 WO2010066684A2 (en) 2010-06-17
WO2010066684A3 true WO2010066684A3 (en) 2010-10-14

Family

ID=42034535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/066540 WO2010066684A2 (en) 2008-12-09 2009-12-07 Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease

Country Status (39)

Country Link
US (6) US8242125B2 (en)
EP (1) EP2376478B1 (en)
JP (1) JP5580330B2 (en)
KR (1) KR101345956B1 (en)
CN (2) CN103193773B (en)
AR (1) AR074499A1 (en)
AU (1) AU2009326110B9 (en)
BR (1) BRPI0922552A2 (en)
CA (1) CA2745922C (en)
CL (1) CL2011001378A1 (en)
CO (1) CO6382119A2 (en)
CR (1) CR20110270A (en)
CU (1) CU24097B1 (en)
CY (1) CY1119091T1 (en)
DK (1) DK2376478T3 (en)
EA (1) EA019681B1 (en)
EC (1) ECSP11011113A (en)
ES (1) ES2633959T3 (en)
HN (1) HN2011001593A (en)
HR (1) HRP20171075T1 (en)
HU (1) HUE035292T2 (en)
IL (1) IL213068A (en)
JO (1) JO3265B1 (en)
LT (1) LT2376478T (en)
MX (1) MX2011006093A (en)
MY (1) MY155649A (en)
NZ (2) NZ601656A (en)
PE (1) PE20110835A1 (en)
PL (1) PL2376478T3 (en)
PT (1) PT2376478T (en)
RS (1) RS56076B1 (en)
SG (1) SG171784A1 (en)
SI (1) SI2376478T1 (en)
SV (1) SV2011003939A (en)
TN (1) TN2011000263A1 (en)
TW (1) TWI429640B (en)
UY (1) UY32302A (en)
WO (1) WO2010066684A2 (en)
ZA (1) ZA201103759B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (en) 2008-09-22 2014-06-09 Array Biopharma Inc Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
AU2011322597B2 (en) * 2010-10-27 2015-09-10 Novartis Ag Dosing regimes for the treatment of ocular vascular disease
CN102786469B (en) * 2011-05-18 2016-09-14 中国医学科学院药物研究所 Adjacent pyridine hydrazide derivatives and preparation method thereof and pharmaceutical composition and purposes
BR112014027359A2 (en) * 2012-05-04 2017-07-18 Novartis Ag modulators of the complementary reaction series and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
KR101315227B1 (en) * 2012-05-30 2013-10-07 엘지디스플레이 주식회사 Display device with integrated touch screen and method for driving the same
JP6155332B2 (en) * 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
ES2710491T3 (en) * 2012-06-28 2019-04-25 Novartis Ag Modulators of the complement pathway and its uses
JP6154897B2 (en) * 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
CN104640855B (en) * 2012-06-28 2017-08-29 诺华股份有限公司 Complement is by way of conditioning agent and application thereof
US9388199B2 (en) * 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US20150191462A1 (en) * 2012-06-28 2015-07-09 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EA201590200A1 (en) * 2012-07-12 2015-08-31 Новартис Аг MODULATORS OF THE COMPLEMENT ACTIVATION WAY AND THEIR APPLICATION
CN103570616B (en) * 2012-07-18 2017-10-20 中国医学科学院药物研究所 N ' straight chains alkanoyl neighbour's pyridine hydrazide derivatives and its preparation method and pharmaceutical composition and purposes
JP6387391B2 (en) 2013-03-14 2018-09-05 ノバルティス アーゲー 2- (1H-Indol-4-ylmethyl) -3H-imidazo [4,5-b] pyridine-6-carbonitrile derivatives as complement factor B inhibitors useful for the treatment of ophthalmic diseases
CN104072481B (en) * 2013-03-28 2016-08-17 宁波市方昌医药有限公司 A kind of Anti-angiogenic compounds
US20150018376A1 (en) * 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
US10174006B2 (en) * 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
EP3028703B1 (en) 2013-07-29 2019-12-04 Kyowa Kirin Co., Ltd. Piperidine derivatives as wnt signaling inhibitor
JP2016535042A (en) * 2013-10-30 2016-11-10 ノバルティス アーゲー 2-Benzyl-benzimidazole complement factor B inhibitor and uses thereof
WO2015118598A1 (en) * 2014-02-06 2015-08-13 株式会社Ｊｏｌｅｄ Display device
JP2017206437A (en) * 2014-08-18 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 4-aminopyridine derivative
JP6444525B2 (en) * 2015-02-27 2018-12-26 ナントバイオ，インコーポレイテッド Pyrimidine derivatives as kinase inhibitors and therapeutic uses thereof
US20180186755A1 (en) * 2015-07-01 2018-07-05 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
PL3322706T3 (en) 2015-07-16 2021-07-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
CN108349942B (en) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 Indolin-2-one derivatives for the treatment of CNS and related diseases
CN108137555B (en) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 Indolin-2-one derivatives useful in the treatment of CNS disorders
PE20181885A1 (en) 2015-11-06 2018-12-07 Hoffmann La Roche DERIVATIVES OF INDOLIN-2-ONA
KR20210010652A (en) 2016-04-04 2021-01-27 록쏘 온콜로지, 인코포레이티드 Methods of treating pediatric cancers
PE20181888A1 (en) 2016-04-04 2018-12-11 Loxo Oncology Inc LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-IL) -PYRAZOLE [1,5-A] PYRIMIDIN-3-IL) -3 -HYDROXYPYRROLIDINE-1-CARBOXAMIDE
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (en) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Method for making (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrolidine-1-carboxamide and its salts
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
KR20190069459A (en) 2016-10-14 2019-06-19 노파르티스 아게 Treatment of eye diseases using inhibitors of CSF-1R
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
CN108586454B (en) * 2018-02-13 2021-02-26 沈阳药科大学 Tetrahydropyrido [4,3-d ] pyrimidine derivatives and application thereof
CN110386892B (en) * 2018-04-16 2020-08-18 新发药业有限公司 Preparation method of 4-fluoro-5-hydroxy-2-methyl-1H-indole
CN110483482A (en) * 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 Indoline -1- Carbox amide, preparation method and its in application pharmaceutically
KR102653681B1 (en) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-lH-PYRAZOLE-4-CARBOXAMIDE
ES2922314T3 (en) 2018-09-10 2022-09-13 Array Biopharma Inc Fused Heterocyclic Compounds as RET Kinase Inhibitors
CN113490666A (en) 2018-12-19 2021-10-08 奥瑞生物药品公司 Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2021134004A1 (en) 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
WO2022033472A1 (en) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr inhibitor compound and use thereof
WO2022055963A1 (en) 2020-09-10 2022-03-17 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
WO2022164789A1 (en) 2021-01-26 2022-08-04 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders
TW202300150A (en) 2021-03-18 2023-01-01 美商薛定諤公司 Cyclic compounds and methods of using same
WO2023139534A1 (en) 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
WO2023187715A1 (en) 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099771A2 (en) * 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004043379A2 (en) * 2002-11-06 2004-05-27 Smithkline Beecham Corporation Chemical compounds
WO2006034833A1 (en) * 2004-09-28 2006-04-06 Novartis Ag Cyclic diarly ureas suitable as tyrosine kinase inhibitors
WO2006059234A2 (en) * 2004-09-15 2006-06-08 Novartis Ag Bicyclic amides as kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1254138E (en) 2000-02-09 2005-09-30 Novartis Ag PYRIDINE DERIVATIVES THAT INHIBIT ANGIOGENESE AND / OR VIRUS TYROSINE KINASE RECEPTOR
ES2318649T3 (en) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS.
GB0126902D0 (en) 2001-11-08 2002-01-02 Novartis Ag Organic compounds
JP4183193B2 (en) * 2002-08-30 2008-11-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Nitrogen-containing aromatic ring derivatives
SE0302324D0 (en) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
GB0420520D0 (en) * 2004-09-15 2004-10-20 Novartis Ag Organic compounds
DOP2006000051A (en) 2005-02-24 2006-08-31 Lilly Co Eli VEGF-R2 INHIBITORS AND METHODS
GT200600411A (en) * 2005-09-13 2007-05-21 Novartis Ag COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR
KR20090023561A (en) 2006-04-07 2009-03-05 노파르티스 아게 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor
JP2010535773A (en) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー Nitrogen-containing bicyclic chemicals for treating viral infections
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TWI440638B (en) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd Heterocyclic compound and pharmaceutical composition thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099771A2 (en) * 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004043379A2 (en) * 2002-11-06 2004-05-27 Smithkline Beecham Corporation Chemical compounds
WO2006059234A2 (en) * 2004-09-15 2006-06-08 Novartis Ag Bicyclic amides as kinase inhibitors
WO2006034833A1 (en) * 2004-09-28 2006-04-06 Novartis Ag Cyclic diarly ureas suitable as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP2376478B1 (en) 2017-04-19
TWI429640B (en) 2014-03-11
US20120245187A1 (en) 2012-09-27
SI2376478T1 (en) 2017-07-31
TW201026686A (en) 2010-07-16
UY32302A (en) 2010-07-30
US8501756B2 (en) 2013-08-06
ES2633959T3 (en) 2017-09-26
US20100168082A1 (en) 2010-07-01
EA019681B1 (en) 2014-05-30
IL213068A (en) 2017-02-28
TN2011000263A1 (en) 2012-12-17
US8242125B2 (en) 2012-08-14
NZ593030A (en) 2013-11-29
RS56076B1 (en) 2017-10-31
CN102307870B (en) 2014-06-18
IL213068A0 (en) 2011-07-31
JP5580330B2 (en) 2014-08-27
CY1119091T1 (en) 2018-01-10
PT2376478T (en) 2017-06-30
PE20110835A1 (en) 2011-11-25
ECSP11011113A (en) 2011-07-29
US8492393B2 (en) 2013-07-23
CA2745922A1 (en) 2010-06-17
CO6382119A2 (en) 2012-02-15
ZA201103759B (en) 2012-01-25
EA201100873A1 (en) 2011-12-30
DK2376478T3 (en) 2017-07-31
CR20110270A (en) 2011-06-28
US8486954B2 (en) 2013-07-16
LT2376478T (en) 2017-07-10
CN103193773A (en) 2013-07-10
JO3265B1 (en) 2018-09-16
SG171784A1 (en) 2011-07-28
AU2009326110A1 (en) 2011-06-23
NZ601656A (en) 2013-11-29
PL2376478T3 (en) 2017-10-31
MX2011006093A (en) 2011-06-21
CU24097B1 (en) 2015-06-30
KR101345956B1 (en) 2014-02-06
US8431584B2 (en) 2013-04-30
AR074499A1 (en) 2011-01-19
US20130005750A1 (en) 2013-01-03
CN103193773B (en) 2014-12-10
US8541432B2 (en) 2013-09-24
HRP20171075T1 (en) 2017-10-06
AU2009326110B2 (en) 2013-09-12
KR20110098799A (en) 2011-09-01
CN102307870A (en) 2012-01-04
HN2011001593A (en) 2014-01-20
US20130005753A1 (en) 2013-01-03
AU2009326110B9 (en) 2013-10-31
HUE035292T2 (en) 2018-05-02
US20130012529A1 (en) 2013-01-10
EP2376478A2 (en) 2011-10-19
CA2745922C (en) 2017-06-27
SV2011003939A (en) 2011-07-28
BRPI0922552A2 (en) 2021-11-03
JP2012511535A (en) 2012-05-24
CL2011001378A1 (en) 2011-11-25
US20130005751A1 (en) 2013-01-03
MY155649A (en) 2015-11-13
WO2010066684A2 (en) 2010-06-17
CU20110129A7 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
WO2010001169A3 (en) Chemical compounds 251
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
EA201000552A1 (en) PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS PROTEINKINASE INHIBITORS IN
MX2012002179A (en) Heterocyclic oxime compounds.
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
MX2012001838A (en) Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2008065068A3 (en) Substituted dihydroimidazoles and their use in the treatment of tumors
MX2014003194A (en) 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase.
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2012094462A3 (en) Heterocyclic compounds for the inhibition of pask
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
MX2012001529A (en) 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators.
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
WO2006138589A3 (en) Opioid receptor ligands
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980156323.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774876

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 213068

Country of ref document: IL

Ref document number: 3860/DELNP/2011

Country of ref document: IN

Ref document number: CR2011-000270

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 593030

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12011501125

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2745922

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 001180-2011

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 2011540046

Country of ref document: JP

Ref document number: MX/A/2011/006093

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: D2011129

Country of ref document: CU

ENP Entry into the national phase

Ref document number: 2009326110

Country of ref document: AU

Date of ref document: 20091207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2011000433

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 201100873

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2009774876

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009774876

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117015822

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: a201107299

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0922552

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110608